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Bacopa monnieri (L.) is widely used in Ayurvedic medicine as a neural tonic for
improving intelligence and memory. Several studies highlighted its efficacy in neuro-
psychiatric diseases but there is no evidence regarding anhedonia. Aim of the present
work was to preclinically and clinically test against anhedonia a standardized B. mon-
nieri extract (20% bacosides). In a mouse model of a depressive-like syndrome
induced by lipopolysaccharide (LPS), the daily administration of the extract (50–
200 mg kg−1, p.o.) for 1 week, dose-dependently counteracted the immobility time in
Porsolt and Tail suspension tests (p < .01). At the sucrose preference test (directly
related to the ability for feeling pleasure) the extract treatment (100 and
200 mg kg−1) counteracted the reduction of sucrose intake induced by LPS (p < .01).
Moreover, B. monnieri significantly reduced cytokines, cortisol, and artemin
LPS-dependent alterations in plasma while increased the brain-derived neurotrophic
factor levels (p < .05). The efficacy of the same extract was tested in a clinical study in
which 42 patients with significant degree of anhedonia (evaluated as Snaith-Hamilton
Pleasure Scale [SHAPS] score ≥ 3) were enrolled. Patients were divided into two
groups and treated with citalopram or citalopram associated with B. monnieri (300 mg
bid) for 4 weeks. The Pears Sample T-test showed a significant improvement (p < .05)
in relevant scales (Hamilton depression rating scale, SHAPS, and strength and difficul-
ties questionnaire) in the extract-treated group in comparison to citalopram alone was
recorded. These data suggest that B. monnieri extract may be effective for the manage-
ment of anhedonia and therefore should be considered for future controlled trials.
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1 | INTRODUCTION
Bacopa monnieri, a plant native to the wetlands of Southern and Eastern
India, is known in India under the name of Brahmi and is traditionally used
in Ayurvedic medicine as neural tonic, sedative, anti-epileptic, memory,
and learning enhancer (Pham et al., 2019). Several preclinical studies have
shown numerous pharmacological effects of this plant, such as improved
memory in Alzheimer's disease and schizophrenia, potential anti-stress,
anticonvulsant and anti-Parkinson's actions and recent clinical trials have
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confirmed the efficacy of B. monnieri on learning and cognitive perfor-
mance (Negi, Singh, & Kushwaha, 2000). Furthermore, numerous preclini-
cal studies have demonstrated the antidepressant effects of a B. monnieri
standardized extracts in paradigms commonly used to evaluate depression
(Banerjee, Hazra, Ghosh, & Mondal, 2014; Sheikh et al., 2007). Moreover,
B. monnieri can inhibit the release of IL-6 and TNF-α from activated
microglia (Nemetchek, Stierle, Stierle, & Lurie, 2017) and increase concen-
tration of the brain-derived neurotrophic factor (BDNF) in rat hippocampus
(Banerjee et al., 2014; Hazra, Kumar, Saha, & Mondal, 2017; Kumar & Mon-
dal, 2016). Lesser evidence exist about the clinical efficacy of B. monnieri, a
double-blind RCT study on mood and stress (Benson et al., 2014) was carried
out on 17 healthy volunteers treated with 320 and 640 mg of extract after
being exposed to stress induced by multitasking: the results showed a cortisol
levels reduction and mood improvement (Benson et al., 2014).
Depression may be intended as the expression of different endo-
phenotypes (Hasler, Drevets, Manji, & Charney, 2004). The association
between psychopathological (impaired reward and cognitive functions,
neurovegetative signs, increased stress sensitivity) and biological (func-
tional and structural brain abnormalities, dysfunctions in neurotransmit-
ters levels, and intracellular signaling) endophenotypes generates
multiplex behavioral manifestations related to different neural circuits
according to the Research Domain Criteria (RDoC) model (Insel, 2014).
Beyond heterogeneity, anhedonia, the reduced ability to experience
pleasure, is a recurrent, transnosographic dimension. It is a hallmark
symptom of major depression, schizophrenia, and other neuropsychiat-
ric disorders that represents a negative prognostic factor and leads to
adverse mental health outcomes across the lifespan and predicts poor
psychosocial functioning. The neural bases of the construct of anhedo-
nia reflects deficits in hedonic capacity and are closely linked to the
constructs of reward valuation, decision-making, anticipation, and moti-
vation (Treadway & Zald, 2011). Since anhedonia is a difficult-to-treat
target, several therapeutic approaches have been proposed, including
psychosocial interventions, antipsychotics (for schizophrenia condi-
tions) (Aleman et al., 2017), antidepressants (in mood disorders) (Craske,
Meuret, Ritz, Treanor, & Dour, 2016), and neuromodulation interven-
tions (in addictive use disorder; Pettorruso et al., 2018; Pettorruso, Di
Giannantonio, De Risio, Martinotti, & Koob, 2019).
On this base, the possibility to intervene on the anhedonic dimen-
sion with a natural complementary approach becomes an intriguing
therapeutic possibility. B. monnieri is a theoretically optimal candidate
to be evaluated. Aim of the present work was to study the efficacy of
a characterized B. monnieri extract in a mouse model of LPS-induced
anhedonia and, in the subsequent clinical phase of the study, to test
the effect of the extract in addition to conventional therapy (TAU) in
patients with this symptom.
2 | MATERIALS AND METHODS
2.1 | Extract and pure Bacoside II
A commercial B. monnieri powder extract (Galeno, Carmignano, Italy)
was used for the tests, batch n. C17070624. Bacoside II was an
international reference standard (purity 98%) from Abacipharm Corp
(Maryland, USA).
2.2 | HPLC-DAD and ESI-TQ-MS/MS apparatus
and conditions
The HPLC analysis was performed on a HPLC 2695 Waters instru-
ment coupled with TQ-Four micro Waters using an ESI source. The
chromatographic separation was performed using a Gemini C18 ana-
lytical column 150 × 2.0 mm (5 μm, particle size, 110 Å) Phenomenex.
The flow rate was 0.35 ml/min and the injection volume was 20 μl.
Mobile phase (water/acetonitrile) was a gradient water starting with
20% of acetonitrile until 80% in 23 min. Identification of peaks was
based on comparisons of ESI-MS/MS spectra with those reported in
the literature and co-injection with standard Bacoside II. Samples
were dissolved in MeOH (1 mg/ml) and filtered in a 0.45 μm mem-
brane filter. Acquisition in full scan MS, positive ion mode from m/z
430 to m/z 1,200. The quantification of the contents of the B. mon-
nieri saponins was performed using HPLC-MS with external standard
method, using Bacoside II (IS, 99.7% pure by HPLC) as standard com-
pound. The HPLC method was validated in terms of linearity, limit of
detection, limit of quantification, precision, accuracy, and robustness
according to the International Conference on Harmonization (ICH)
guidelines (ICH, 2005).
2.3 | Preclinical investigation
2.3.1 | Animals
Male CD-1 albino mice (Envigo, Varese, Italy) weighing approxi-
mately 22–25 g at the beginning of the experimental procedure,
were used. Animals were housed in CeSAL (Centro Stabulazione
Animali da Laboratorio, University of Florence) and used at least
1 week after their arrival. A maximum of 12 mice were housed per
cage (size 26 × 41 cm); animals were fed a standard laboratory
diet and tap water ad libitum, and kept at 23 ± 1C with a 12 h
light/dark cycle, light at 7 a.m. All animal manipulations were car-
ried out according to the Directive 2010/63/EU of the European
parliament and of the European Union council (September 22,
2010) on the protection of animals used for scientific purposes.
The ethical policy of the University of Florence complies with the
Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996; University of Florence assurance number: A5278-01). For-
mal approval to conduct the experiments described was obtained
from the Italian Ministry of Health (No. 54/2014-B) and from the
Animal Subjects Review Board of the University of Florence.
Experiments involving animals have been reported according to
ARRIVE guidelines (McGrath & Lilley, 2015). All efforts were made
to minimize animal suffering and to reduce the number of
animals used.
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2.3.2 | B. monnieri treatment
The extract of B. monnieri (L.) Pennell (dry extract, 20% bacosides, Gal-
eno Srl, Italy) was suspended in 1% carboxymethylcellulose sodium
salt (CMC) and orally (p.o.) administered every day for 1 week in a
range dose of 50–200 mg kg−1. Control group was treated with
vehicle.
2.3.3 | LPS-induced anhedonia
Lipopolysaccharide (LPS) from Escherichia coli was purchased from
Sigma-Aldrich, freshly dissolved in sterile saline and injected intraperi-
toneally (i.p.) at the dose of 1.25 mg kg−1 (Biesmans et al., 2013) after
1 week of B. monnieri treatment, 1 hr after the last administration of
the extract. Behavioral tests were performed before 6 and 24 hr after
LPS administration. Control group was treated with vehicle.
2.3.4 | Forced swimming test
The forced swimming test used was the same described by Porsolt, Le
Pichon, and Jalfre (1977). More information are reported in
Supporting Information.
2.3.5 | Tail suspension test
A piece of tape was adhered to the upper middle of the tail of each ani-
mal, creating a flap with the overlap of tape. Mice were suspended from
a plastic rod mounted 50 cm above the surface by fastening the tail to
the rod with adhesive tape. The duration of the test was 6 min and the
immobility time was measured in the first 2 min, when animals react to
the inescapable stress, and in the last 4 min of the test, when the behav-
ioral despair is established. Immobility was defined as the absence of any
limb or body movements, except those caused by respiration.
2.3.6 | Sucrose preference
The preference for 2% sucrose solution was examined as a measured
for anhedonia. More information are reported in Supporting
Information.
2.3.7 | Tissue collection and measurements of
soluble factors
At the end of the behavioral test session, 24 hr after LPS administra-
tion, animals were sacrificed by decapitation, the prefrontal cortex
was collected and frozen using liquid nitrogen. IL-6, IL-1β, cortisol,
BDNF, and ART were detected using ELISA kit according to the man-
ufacturer instructions.
2.3.8 | Determination of thiobarbituric acid
reactive substances
Thiobarbituric acid reactive substances (TBARS) were quantified in
brain tissue homogenates as described previously, with some minor
modifications (Pan et al., 2009).
About 100 μg of prefrontal cortex tissue homogenate were
added to 4 ml reaction mixture consisting of 36 mM thiobarbituric
acid (Sigma-Aldrich, Milan, Italy) solubilized in 10% CH3COOH,
0.2% SDS, pH was adjusted to 4.0 with NaOH. The mixture was
heated for 60 min at 100C and the reaction was stopped by plac-
ing the vials in ice bath for 10 min. After centrifugation (at 1,600g
at 4C for 10 min) the absorbance of the supernatant was measured
at 532 nm (Perkin-Elmer spectrometer, Monza, Italy) and TBARS
were quantified in μmoles/milligram of total protein using
1,1,3,3-tetramethoxypropane as standard. Protein homogenate
concentration was measured by bicinchoninic acid (BCA; Sigma-
Aldrich) assay.
2.3.9 | Catalase activity
Catalase activity was measured in the supernatant of brain tissue
homogenate by Amplex Red Catalase Assay Kit (Invitrogen, Monza,
Italy) following the manufacturer's instructions as previously described
(Zanardelli et al., 2014). Protein concentration was quantified by
bicinchoninic acid assay (Sigma-Aldrich). Catalase activity for each
sample was normalized to protein concentration. Control conditions
in the absence of treatment were set as 100%.
2.4 | Clinical investigation
2.4.1 | Sample
Our study was conducted on a sample of patients described in
Table 1, dealing with outpatients and Day Hospital of the Psychiatric
unit in the University Hospital of Florence and Institute of Neurosci-
ence (INS), which had a clinically significant degree of anhedonia (eval-
uated as SHAPS score ≥ 3) being diagnosed for major depression
(DSM 5.0) and after adequate treatment with citalopram and stable
for 4 weeks with an unsatisfactory response.
2.4.2 | Assessment
To measure the severity of anhedonia, every participant was adminis-
tered the Snaith–Hamilton Pleasure Scale (SHAPS; Snaith et al., 1995)
and the Temporal Experience of Pleasure Scales (TEPS) scale immedi-
ately before and after the 4-week treatment period. Moreover, the
following scales were administered and evaluated: strengths and diffi-
culties questionnaire (SDQ), patient health questionnaire, Hamilton
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depression rating scale (HAM-D; Hamilton et al., 1960), credibility-
expectation questionnaire (CEQ), and clinical global impression (CGI).
2.4.3 | Treatment
Patients were randomly assigned to two groups. The first group
(n = 23) was treated only with (40 mg) citalopram for the follow
4 weeks (TAU); the second group (n = 19) with conventional therapy
associated with a nutraceutical supplement consisting of B. monnieri
extract titrated at 20% in bacosides (one capsule 300 mg twice daily).
The treatment lasted 4 weeks.
2.4.4 | Statistical analysis
For preclinical study, behavioral measurements were performed on 16
mice for each treatment carried out in two different experimental
sets. Results were expressed as means ± SEM and the analysis of vari-
ance was performed by ANOVA. A Bonferroni's significant difference
procedure was used as post-hoc comparison. p Values of less than .05
and .01 were considered significant. Data were analyzed using the
“Origin 8.1” software. For clinical study, in order to characterize the
study sample, a descriptive statistical analysis was performed. In par-
ticular for the categorical variables study the chi-square test was used,
while the t-test was used for the continuous variables. For some vari-
ables, in addition to the paired t-test, a nonparametric test; a multivar-
iate linear model was therefore used to study the association
between the use of the bacopa and the outcome of the tests and to
correct for the baseline CIB-3 imbalance.
Pearson's r coefficient was calculated to evaluate the correlation
of clinical variables.
Statistical tests were two-tailed. Level of significance was set
at p = .05.
All analyses were performed on study completers and were car-
ried out using the SPSS statistical software version 15.0 (SPSS, Inc.,
Chicago, 2007).
3 | RESULTS
3.1 | Characterization of the commercial extract
B. monnieri commercial extract was characterized by HPLC-PDA-MS
analysis. The chromatogram of B. monnieri commercial extract solubi-
lized in MeOH (100 ng/μl) displayed four principal peaks related to
Bacopa saponins with retention times of 16.5, 16.8, 17.2, and
17.5 min. The identification of Bacopaside II with the peak having a
retention time of 16.8 min was based on the co-elution with the refer-
ence standard (20 ng/μl in methanol) and confirmed by the m/z 951.8
of the [M + Na]+.
The other three peaks of the chromatogram of B. monnieri com-
mercial extract at 16.5, 17.2, and 17.5 min were unambiguously attrib-
uted to Bacoside A3, Bacopasaponin C, and Bacopaside X,
respectively. Peak at 16.5 was assigned to Bacoside A3, with the same
MS data of Bacopaside II, which represents its isomer. Bacopasaponin
C and Bacopaside X were assigned to the peaks at 17.2 and 17.5 min
because the characteristic MS data (m/z 921.8 or 921.9 of the [M
+ Na]+), as reported in Figure 1.
The repeatability was determined by HPLC analysis of three sam-
ples, and the RSD of the contents was calculated for the four major
constituents. RSD values ranged between 0.55 and 3.80. Lastly, the
external standard method was applied to quantify each compound,
using a regression curve, with each point determined in triplicate. The
resulting percentage of total saponins expressed as Bacopaside II was
ca. 20%.
3.2 | Preclinical results
3.2.1 | Forced swimming test
We evaluated the protective effect of B. monnieri extract on LPS-
induced anhedonia in the mouse. In the forced swimming test,
behavioral despair was evaluated by measuring the time during
which the animal remains immobile after being placed in a water
filled cylinder from which it cannot escape (Figure 2). LPS
(1.25 mg kg−1) acute administration was able to significantly increase
the immobility time of the animals in this test both at 6 and 24 hr
after injection with respect to the control group (168.0 ± 13.7 s vs.
63.5 ± 9.2 s at 6 hr and 104.8 ± 14.9 s vs. 40.0 ± 7.9 s at 24 hr,
respectively). Daily administration of B. monnieri extract for 1 week
(50–200 mg kg−1) was able to counteract the immobility time
induced by LPS in a dose-dependent manner (Figure 2). The higher
dose (200 mg kg−1) significantly diminished the reduction of move-
ments induced by LPS systemic injection at 6 and 24 hr (30.6
± 17.4 s and 31.2 ± 7.2 s, respectively). The dose of 100 mg kg−1
was still active at both time points but with a lower efficacy (70.3
± 21.0 s and 61.0 ± 7.6 s, respectively) while the dose of 50 mg kg−1
was inactive both at 6 hr than 24 hr (156.3 ± 36.4 s and 95.7 ± 8.7 s,
respectively).
TABLE 1 Study of the sample
Sample 42 Patients, 19 cases (BM), and 23 controls (TAU)
Sex F > M (64.3% N = 27 vs. 35.7% N = 15)
Age In cases of average age 47.22 years (DS = 12.891),
between checks 48.53 years (DS = 13.443)
For the years of illness, the two groups show no
statistically significant differences (p < .05): The
cases have average disease duration of
15.55 years (DS = 10.828) and the controls of
8.76 years (DS = 11.098)
Average
school age
12.47 years (DS 3.31)
Smoke 21% smokers, 21.4% N = 9 smokers
Job Employees 59.5% N = 25, freelancers 9% N = 5,
retired 16.7% N = 7, unemployed 11.9% N = 5
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3.2.2 | Tail suspension test
Similar results were obtained in the tail suspension test (Figure 3). In
this test, behavioral despair was evaluated by measuring the time dur-
ing which the animal remains immobile after being suspended by the
tail. Repeated treatment with B. monnieri extract counteracted the
increased of immobility time induced by LPS acute injection in a dose-
dependent manner. The group treated with the higher dose
(200 mg kg−1) reached the value of 59.4 ± 7.5 s at 6 hr and 37.8
± 12.2 s at 24 hr after LPS injection in comparison to the values of
F IGURE 2 Forced swimming test. Effect of B. monnieri extract on
LPS-induced anhedonic-like behavior. B. monnieri (50–200 mg kg−1)
was p.o. daily administered for 1 week before the acute i.p. injection
of LPS (1.25 mg kg−1). The immobility time was evaluated before and
after LPS administration (6 and 24 hr). Each value represents the
mean of 16 mice performed in two different experimental sets. Data
are shown as mean ± SEM; ^p < .05 and ^^p < .01 versus vehicle
+ vehicle-treated mice; *p < .05 and **p < .01 versus vehicle + LPS-
treated mice. LPS, lipopolysaccharide
F IGURE 1 MS spectra of the positive ions of the major four peaks corresponding to the four detected saponins [Colour figure can be viewed
at wileyonlinelibrary.com]
F IGURE 3 Tail suspension test. Effect of B. monnieri extract on
LPS-induced anhedonic-like behavior. B. monnieri (50–200 mg kg−1)
was p.o. daily administered for 1 week before the acute i.p. injection
of LPS (1.25 mg kg−1). The immobility time was evaluated before and
after LPS administration (6 and 24 hr). Each value represents the
mean of 16 mice performed in two different experimental sets. Data
are shown as mean ± SEM; ^p < .05 and ^^p < .01 versus vehicle
+ vehicle-treated mice; *p < .05 and **p < .01 versus vehicle + LPS-
treated mice. LPS, lipopolysaccharide
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116.6 ± 9.8 s and 87.3 ± 3.4 s reached by LPS-treated group
(Figure 3). The dose 100 mg kg−1 was less effective while the lower
dosage was inactive.
3.2.3 | Sucrose preference test
Another anhedonic-like behavior was the reduction of sucrose intake.
Six and twenty-four hours after LPS injection, mice in the LPS group
showed significantly less preference for sucrose than animals in the
control group (45.2% vs 75.4% at 6 hr and 31.5% vs 74.7% at 24 hr;
Figure 4). B. monnieri extract counteracted this phenomenon at both
time points when was administered at the dose of 100 and
200 mg kg−1. The lower dosage was ineffective.
3.2.4 | Measurement of soluble factors
Moreover, LPS injection significantly increased the prefrontal cortex
concentration of IL-6, IL-1β, cortisol, and ARTN with respect to the
control group 24 hr after injection. No alteration was recorded for the
neurotrophic factor BDNF (Figure 5). B. monnieri (200 mg kg−1)
F IGURE 4 Sucrose preference test. Effect of B. monnieri extract
on LPS-induced anhedonic-like behavior. B. monnieri (50–
200 mg kg−1) was p.o. daily administered for 1 week before the acute
i.p. injection of LPS (1.25 mg kg−1). The sucrose preference was
evaluated after 6 and 24 hr LPS administration. Each value represents
the mean of 16 mice performed in two different experimental sets.
Data are shown as mean ± SEM; ^^p < .01 versus vehicle + vehicle-
treated mice; *p < .05 and **p < .01 versus vehicle + LPS-treated
mice. LPS, lipopolysaccharide
F IGURE 5 Measurements of soluble factors in the prefrontal
cortex. Effect of B. monnieri extract on LPS-induced Il-6, Il-1β, cortisol,
BDNF, and ARTN alterations. B. monnieri (200 mg kg−1) was p.o. daily
administered for 1 week before the acute i.p. injection of LPS
(1.25 mg kg−1). The measurements of Il-6, Il-1β, cortisol, BDNF, and
ARTN were performed in the prefrontal cortex 24 hr after LPS
administration. Each value represents the mean of 16 mice performed
in two different experimental sets. Data are shown as mean ± SEM;
^p < .05 versus vehicle + vehicle-treated mice; *p < .05 versus
vehicle + LPS-treated mice. ARTN, artemin; BDNF, brain-derived
neurotrophic factor; LPS, lipopolysaccharide
F IGURE 6 Evaluation of TBARS and catalase activity in the
prefrontal cortex. Effect of B. monnieri extract on LPS-induced
oxidative stress and enzymatic alterations. B. monnieri (200 mg kg−1)
was p.o. daily administered for 1 week before the acute i.p. injection
of LPS (1.25 mg kg−1). The measurements of (a) TBARS and (b)
catalase activity were performed in the prefrontal cortex 24 hr after
LPS administration. Each value represents the mean of 16 mice
performed in two different experimental sets. Data are shown as
mean ± SEM; ^^p < .01 versus vehicle + vehicle-treated mice;
**p < .01 versus vehicle + LPS-treated mice. LPS, lipopolysaccharide;
TBARS, thiobarbituric acid reactive substances
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significantly reduced the LPS-alterations recorded for IL-6, IL-1β, cor-
tisol, and ARTN while increased the BDNF value with respect to con-
trol and LPS group (Figure 5).
3.2.5 | Effect of B. monnieri on oxidative stress and
catalase activity
Aimed to evaluate the protective effect of B. monnieri treatment
against LPS-induced oxidative damage, we analyzed the lipid perox-
idation measuring TBARS levels in the prefrontal cortex. Acute
injection of LPS induced an alteration of oxidative stress parameter
evaluated as a significantly increased of TBARS levels in compari-
son to the control groups, B. monnieri treatment restored the unbal-
ance as shown in Figure 6a. Moreover, the lipopolysaccharide
administration promoted a decrease in the catalase activity that
was fully counteracted by B. monnieri repeated treatment
(Figure 6b).
3.3 | Clinical results
Forty-two patients (Table 1) with anhedonia (SHAPS ≥ 3) and unsatis-
factory response to drug therapy (CGI-S ≥ 3 and CGI-I between 3 and
7) were consequently enrolled, a first group (cases) of 19 patients
have been prescribed B. monnieri extract in 300 mg tablets to be taken
twice a day, for 4 weeks of treatment, while the second of 23 subjects
(controls) with the same characteristics of the cases, which were
treated with citalopram 40 mg (TAU).
In Figure 7, the differences in clinical outcomes post-treatment in
the group of patients treated with B. monnieri compared to the group
treated with citalopram 40 mg (TAU) are reported. Significant differ-
ences were measured for HAM-D, SHAPS, and SDQ. Raw data of
each group pre- and post-treatment are reported in the Table S1. In
the group treated with B. monnieri, there was no statistically signifi-
cant correlation between the scores of both of the CEQ subscales and
the T1 outcomes, excluding a possible autosuggestion effect by the
patient. In the light of these data, the expectation and credibility in
F IGURE 7 Clinical outcomes post-treatment in the group of patients treated with B. monnieri compared to the group treated with citalopram
40 mg (TAU). The first group (n = 21) was treated only with (40 mg) citalopram for the follow 4 weeks (TAU); the second group (n = 19) with
conventional therapy associated with a nutraceutical supplement consisting of B. monnieri extract titrated at 20% in bacosides (one capsule
300 mg twice daily). The treatment lasted 4 weeks. Significant differences were measured for HAM-D, SHAPS, and SDQ. *p < .05 and **p < .01
versus TAU. HAM-D, Hamilton depression rating scale; SHAPS, Snaith–Hamilton pleasure scale; SDQ, strength and difficulties questionnaire
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the treatment of augmentation would not seem to be relevant for the
final answer.
4 | DISCUSSION
Considering our initial hypothesis, this study indicates that B. monnieri
extract can reduce anhedonia-like behavior in animals and anhedonia-
related symptoms in humans. In mice, the repeated administration of
100 and 200 mg kg−1 extract, dose-dependently, reverted the patho-
logical alterations induced by LPS. Efficacy was highlighted by differ-
ent paradigms. The forced swimming test induces a “state of despair”
that immobilizes the animal in swimming (Carbajal, Ravelo, Molina,
Mas, & Arruzazabala Mde, 2009). This test is considered to have
proven reliability and validity (Porsolt et al., 1977) for the analysis of
antidepressants. The efficacy of Bacopa in this test was confirmed in
the similar tail suspension analysis but also in the sucrose preference
test that represents the most indicative analysis for anhedonia evalua-
tion (Liu et al., 2018).
Based on the clinical evidence about the involvement of inflam-
matory processes in the pathogenesis of depression (Dantzer, O'Con-
nor, Freund, Johnson, & Kelley, 2008), LPS is one of the most used
models of inflammation-associated depression. Behavioral studies in
rodents have shown that systemic LPS injection, by a potent activa-
tion of the immune response, induces a sickness response, character-
ized by social withdrawal, fatigue, anorexia, and alterations in sleep
patterns and cognition, followed by a behavior similar to clinically rele-
vant symptoms of depression in humans, including anhedonia
(Biesmans et al., 2016; Henry et al., 2008; Kang et al., 2011; O'Connor
et al., 2009).
The inflammatory response induced by LPS parallels with the pro-
duction of pro-inflammatory cytokines and the cortisol-dependent
depressive-like behavior promoted by chronic stress in laboratory ani-
mal (Knapp et al., 2011). Interestingly, treatment with antidepressants,
besides normalizing depressive behavior induced by bacterial endo-
toxin, decreases pro-inflammatory cytokines' level (Castanon, Leon-
ard, Neveu, & Yirmiya, 2002).
In the present results, we showed enhanced brain levels of the
pro-inflammatory cytokines IL-1β and IL6 after LPS treatment. Bacopa
extract significantly prevented these alterations suggesting anti-
inflammatory effects of this product in the CNS. Accordingly, Neme-
tchek et al. (2017) showed that B. monnieri, as well as Bacoside A, sig-
nificantly inhibited the release of TNF-α and IL-6 from LPS-activated
microglial cells.
Moreover, it is known that activation of the immune system cau-
ses disruption of the HPA axis, a physiological recurrence often
observed in depression (Capuron & Miller, 2011). According to previ-
ous results (Goble et al., 2001; Silva & Madeira, 2012), we found that
systemic injection of LPS significantly increased brain cortisol levels.
In this condition, the treatment with B. monnieri extract significantly
prevented the HPA axis dysregulation.
In close relationship with the inflammatory state of the CNS, the
altered redox unbalance plays a critical role in the pathophysiology of
several neuropsychiatric disorders (Floyd, 1999). Brain tissue is partic-
ularly exposed to reactive oxygen species since 20% of total body
oxygen is normally metabolized by brain in the presence of a limited
amount of antioxidant strategies (Floyd & Carney, 1992). In situations
where the generation of free radicals exceeds the capacity of antioxi-
dant defense, oxidative stress may lead to membrane degradation,
cellular dysfunction, and apoptosis (Ott, Gogvadze, Orrenius, &
Zhivotovsky, 2007). Recent studies reported enhanced concentrations
of lipid peroxidation products and alterations of the major antioxidant
enzymes in patients with affective disorders, in particular with depres-
sion (Floyd, 1999; Ozcan, Gulec, Ozerol, Polat, & Akyol, 2004;
Sarandol et al., 2007); these features were sensitive to antidepressant
therapies (Machado-Vieira, Salvadore, Luckenbaugh, Manji, & Zarate
Jr., 2008). B. monnieri treatment was able to restore the oxidative
damage occurring in the brain of LPS-treated animals, preventing
lipoperoxidation and enhancing the activity of the peroxisome-charac-
teristic detoxifying enzyme catalase.
Interestingly, LPS did not alter the concentration of the neuronal
factor BDNF but increased levels of ARTN, a factor of glial origin
involved in depression signaling (Di Cesare Mannelli et al., 2011). B.
monnieri treatment increased BDNF (considered as a marker of brain
functionality increased after antidepressants treatment; Tsai, Hong, &
Liou, 2010) without alter the LPS-induced increase of ARTN
suggesting a possible role of these factors, and the consequent cellular
plasticity, in the anti-anhedonic effect of the extract. On this base, the
extract of B. monnieri was clinically tested. Subjects were evaluated by
the MINI (Sheehan et al., 1998) to have a diagnosis standardized
according to the DSM 5.0 criteria. After treatment, the group treated
with B. monnieri extract showed significant lower value of SHAPS and
HAM-D in comparison to TAU group.
Despite the exploratory characteristics of this study (it is an open
study with a low number of samples), various corrective measures
have been done to validate it. In order to characterize the study sam-
ple, a descriptive statistical analysis was performed, in particular for
the categorical variables study the chi-square test was used, while the
t-test was used for the continuous variables. From the first analysis,
the two groups were found to be homogeneous for almost all the clin-
ical variables considered, with the exception of CGI3 (p < .01).
To compensate for the lack of a placebo-controlled study, consid-
ering the probability of autosuggestion of the patients treated with
“natural medicine,” it was decided to provide a scale to measure that
variable to the base line in order to limit its potential confusing effect.
For this purpose, the credibility/expectancy questionnaire (CEQ),
developed by Devilly and Borkovec (2000). The credibility of the
treatment refers to how credible, convincing and logical the treatment
seems to the patient, while the expectation of treatment refers to the
actual improvement that the patient feels will be achieved by him/her
personally. The CEQ showed a high internal consistency and good
test–retest reliability.
It has been postulated that credibility with regard to treatment
and expectation may be modifiable during treatment. It is also likely
that expectation is a stronger predictor of the treatment outcome
than its credibility (Goossens, Vlaeyen, Hidding, Kole-Snijders, &
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Evers, 2005). A critical issue of the studies in literature is that they
have only evaluated the pre-treatment phase immediately prior to the
onset of therapy, which means that patients may have difficulty in
judging what outcome they might achieve. It is to be specified, there-
fore, that in our study the CEQ was completed immediately after the
patient had obtained the necessary treatment explanations, so that
the patient was able to judge the credibility of the treatment and
mature one's expectation.
Devilly and Borkovec argued that even if a patient thinks a new
treatment is credible, this may differ from what he really feels. The
authors hypothesized that expectation may be more related to an
emotional aspect than the credibility that is most based on cognitive
elements, and therefore may have a higher level of association with
the final outcome of treatment, at least in Psychotherapy (Devilly &
Borkovec, 2000). The authors argue that the sub-scale of credibility is
more closely related to the logical thinking processes of patients,
while the subscale of expectation (“how much is really expected to
improve?”) is functionally more linked to affective processes similar to
those involved in hope or faith. Our study, based on the difference in
the magnitude of R2's change for expectation and credibility, did not
find clear indications for their hypothesis.
In conclusion, we evaluated a possible effect of a standardized
extract of B. monnieri on positive symptoms, especially anhedonia,
regardless of categorical diagnosis. The hypothesis of a possible thera-
peutic application of the botanical on the specific size was initially
tested in an animal model that reflected the theoretical construct,
targeting specific neurocircuits. The results of the preclinical phase
were the basis on which to build the next clinical trial. The significant
positive impact of B. monnieri treatment in patients was demon-
strated. These results reflect the opportunities in applying the RDoC
concept to clinical research, and it would of interest to investigate the
clinical effect of B. monnieri on the same dimension, anhedonia, in clin-
ical condition different from depression such as negative symptoms in
schizophrenia. A harmonization of the models is still needed to effec-
tively isolate the symptoms of “negative valence” in depression and
other mental illnesses, and advances their translation to treatment. In
particular in the field of Complementary Therapy (CAM), an increas-
ingly evolving field in terms of clinical use but poorly of valid scientific
evidence and studies conducted with rigorous scientific criteria
according with current neuroscience research. Our work, although it
presents all the limits of an exploratory study, may serve as a proce-
dural model for other neurobiological domains, creating the bases for
producing a more rigorous and translator clinical research in the field
of integrative medicine.
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